PMID- 26031521
OWN - NLM
STAT- MEDLINE
DCOM- 20160112
LR  - 20200717
IS  - 0253-2727 (Print)
IS  - 2707-9740 (Electronic)
IS  - 0253-2727 (Linking)
VI  - 36
IP  - 5
DP  - 2015 May
TI  - [The clinical efficacy of all-trans retinoic acid plus arsenic trioxide in 177 
      newly diagnosed acute promyelocytic leukemia patients].
PG  - 372-7
LID - 10.3760/cma.j.issn.0253-2727.2015.05.004 [doi]
AB  - OBJECTIVE: To investigate the clinical efficacy of all-trans retinoic acid (ATRA) 
      plus arsenic trioxide (ATO) in induction and maintenance therapy in newly 
      diagnosed acute promyelocytic leukemia (APL). METHODS: A retrospective analysis 
      of 298 newly diagnosed APL patients from the department of hematology, First 
      Affiliated Hospital of Zhejiang University since September 2004 to December 2013, 
      including 177 cases with ATRA plus ATO and 116 ATRA plus chemotherapy (CT), was 
      performed to investigate the clinical efficacy between the low-intermediate 
      (WBC</=10x10(9)/L) and high (WBC>10x10(9)/L) risk APL patients, respectively. RESULTS: 
      For the low-intermediate risk patients, the relapse rate in ATRA plus CT and ATRA 
      plus ATO are 22.0% and 6.1% (P=0.004), respectively; the 3 years estimated 
      relapse-free survival (RFS) are 78.0% and 92.9% (P=0.021), respectively. For the 
      high risk patients, the relapse rate in ATRA plus CT and ATRA plus ATO are 25.0% 
      and 5.2% (P=0.035), respectively; the 3 years estimated RFS rate were 80.8% and 
      93.0% (P=0.021), respectively. But the rate of early death (ED), complete 
      remission (CR) and overall survival (OS) between the two therapy protocols had no 
      statistical difference (P>0.05). CONCLUSION: ATRA plus ATO in induction and 
      maintenance therapy might prolong the RFS time of the low-intermediate risk APL 
      patients and decrease the relapse rate of the low, intermediate and high risk APL 
      patients.
FAU - Lu, Ying
AU  - Lu Y
AD  - Department & Institute of Hematology, The First Affiliated Hospital of Zhejiang 
      University, Hangzhou 310003, China.
FAU - Li, Fenglin
AU  - Li F
AD  - Department & Institute of Hematology, The First Affiliated Hospital of Zhejiang 
      University, Hangzhou 310003, China.
FAU - Mu, Qitian
AU  - Mu Q
AD  - Department & Institute of Hematology, The First Affiliated Hospital of Zhejiang 
      University, Hangzhou 310003, China.
FAU - Meng, Haitao
AU  - Meng H
AD  - Department & Institute of Hematology, The First Affiliated Hospital of Zhejiang 
      University, Hangzhou 310003, China.
FAU - Qian, Wenbin
AU  - Qian W
AD  - Department & Institute of Hematology, The First Affiliated Hospital of Zhejiang 
      University, Hangzhou 310003, China.
FAU - Tong, Hongyan
AU  - Tong H
AD  - Department & Institute of Hematology, The First Affiliated Hospital of Zhejiang 
      University, Hangzhou 310003, China.
FAU - Mai, Wenyuan
AU  - Mai W
AD  - Department & Institute of Hematology, The First Affiliated Hospital of Zhejiang 
      University, Hangzhou 310003, China.
FAU - Pei, Renzhi
AU  - Pei R
AD  - Department & Institute of Hematology, The First Affiliated Hospital of Zhejiang 
      University, Hangzhou 310003, China.
FAU - Yu, Mengxia
AU  - Yu M
AD  - Department & Institute of Hematology, The First Affiliated Hospital of Zhejiang 
      University, Hangzhou 310003, China.
FAU - Zhao, Xiaoying
AU  - Zhao X
AD  - Department & Institute of Hematology, The First Affiliated Hospital of Zhejiang 
      University, Hangzhou 310003, China.
FAU - Jin, Jie
AU  - Jin J
AD  - Department & Institute of Hematology, The First Affiliated Hospital of Zhejiang 
      University, Hangzhou 310003, China.
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhonghua Xue Ye Xue Za Zhi
JT  - Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
JID - 8212398
RN  - 0 (Arsenicals)
RN  - 0 (Oxides)
RN  - 5688UTC01R (Tretinoin)
RN  - S7V92P67HO (Arsenic Trioxide)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols
MH  - Arsenic Trioxide
MH  - Arsenicals
MH  - Humans
MH  - *Leukemia, Promyelocytic, Acute
MH  - Oxides
MH  - Recurrence
MH  - Remission Induction
MH  - Retrospective Studies
MH  - Survival Rate
MH  - Tretinoin
PMC - PMC7342586
EDAT- 2015/06/03 06:00
MHDA- 2016/01/13 06:00
PMCR- 2015/05/01
CRDT- 2015/06/03 06:00
PHST- 2015/06/03 06:00 [entrez]
PHST- 2015/06/03 06:00 [pubmed]
PHST- 2016/01/13 06:00 [medline]
PHST- 2015/05/01 00:00 [pmc-release]
AID - cjh-36-05-372 [pii]
AID - 10.3760/cma.j.issn.0253-2727.2015.05.004 [doi]
PST - ppublish
SO  - Zhonghua Xue Ye Xue Za Zhi. 2015 May;36(5):372-7. doi: 
      10.3760/cma.j.issn.0253-2727.2015.05.004.